WinstonWınston
Back
Medistim ASA logo

Medistim ASA

MEDI.OL
77
Medical - Devices · Healthcare
Also trades as: 0OCD.L
Price
kr 246.00
+13.00 (+5.58%)
Market Cap
kr 4.50B
Exchange
Oslo Stock Exchange
Winston Score
77
Winston is happy
A high-quality business with solid fundamentals.
Data as of Aug 23, 2026 · filings through Mar 31, 2026
How the score breaks down
Quality
Strong
Growth
Strong
Cash Flow
Exceptional
Stability
Exceptional
Valuation
Good
Dividends
Strong

Winston Score History

The full picture

Medistim is a Norwegian medical device company that makes specialized tools used by heart surgeons during operations. Its main products are ultrasound-based systems that help surgeons check blood flow in real time while performing bypass and heart valve surgeries. The company sells primarily to hospitals and cardiac surgery centers, and it is one of the few companies in the world focused specifically on this narrow but critical niche of intraoperative blood flow measurement.

Medistim makes money by selling its hardware systems to hospitals and then generating recurring revenue from disposable probes and software that surgeons use during each procedure. The company operates globally, with a strong presence in Europe and growing sales in North America and Asia, and its deep specialization in a technically demanding field gives it a durable competitive position with limited direct rivals. The key growth driver is the gradual expansion of cardiac surgery volumes worldwide, though its small size and dependence on a narrow product category mean any slowdown in hospital capital spending could meaningfully pressure results.

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+11.1% YoY

YoY Growth Rate

Steady revenue growth

EPS Growth

-7.2% YoY

YoY Growth Rate

Earnings declining

R&D Spend

kr 45M/ year

Rising (+27% vs prior year)

6.4% of revenue

Below sector average (18%)

R&D investment increasing — building for the future

Insider Activity

29.0%ownership

Flat

Insider ownership roughly steady over the past year

Cash Position

Cash flow positive

kr 210M cash & investments

Quarterly Free Cash Flow

Company generates more cash than it spends — no dilution risk from fundraising

Growth + cash flow

Medistim ASA is a rare growth stock that's already generating positive cash flow while growing at 11%. The Winston Score doesn't fully credit this transition from "burner" to "earner."

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Share count broadly stable

+0.1% over 4y

The share count has stayed roughly flat over this period — little dilution or buyback activity.

Diluted shares outstanding: 18.2M (2021) → 18.3M (2025)

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale
Gross Margin
47.5%
Healthy — 47.5% gross margin
Profit after running costs
Operating Margin
28.3%
Excellent — 28.3% operating margin
Return on the money invested
ROCE
37.4%
Exceptional — 37.4% return on capital

ROIC above 25%. Every dollar invested in the business earns more than 25 cents back per year.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth
Sales YoY
+17.9%
Fast-growing sales (+17.9% YoY)
Profit growth
EPS YoY
+27.1%
Earnings growing fast (+27.1% YoY)

Earnings growing 25%+ a year. The compounder zone.

How steady the profit is
EPS Consistency
6/8 quarters
Earnings grew in most of the last 8 quarters

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash
Cash Conversion
115%
Turns 115% of profit into real cash
Spare cash per sale
FCF Margin
15.8%
Converts sales into free cash efficiently (15.8%)

FCF margin between 10% and 20%. Every $100 in sales becomes $10 to $20 in real cash.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns
Debt / Equity
0.02
Conservative — low debt load (0.02)
Covers its interest
Interest Cover
8.38x
Comfortably covers interest (8.4x)

Interest coverage above 8. Profits cover interest many times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit
P/E Ratio (TTM)
28.8x
Growth-priced — P/E 28.8

P/E above the market average. People are paying up for expected growth.

Cheaper or dearer next year
P/E vs Forward
+1.3
GROWING
Earnings expected to grow — slightly cheaper on forward P/E

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend
Dividend Yield
3.25%
Moderate income — 3.25% yield

Standard yield zone for stable dividend payers. A meaningful piece of total return.

Dividend record
Dividend Growth
+95.7%
Dividend growing fast (95.7% YoY)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial